All In Biotech

Drug Trial Radar · NCT05594095

SNF Platform Study of HR+/ HER2-advanced Breast Cancer

Precision Platform Study of HR+/ HER2-advanced Breast Cancer Based on SNF Typing (A Prospective, Open-label, Multi-center, Phase II Platform Study)

Last checked: Nov 19, 2026Latest source record: Oct 4, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingRandomized with 620 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

620

Planned (sponsor's estimate)

Start

Dec 30, 2022

Primary completion

Dec 1, 2025

Study completion Dec 1, 2026

Sponsor

Lead sponsor
Fudan UniversityAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
Peking University Cancer Hospital & Institute; First Hospital of China Medical University; Sun Yat-sen University; First Affiliated Hospital Xi'an Jiaotong University; Chongqing University Cancer Hospital; Northern Jiangsu People's Hospital; Fujian Medical University Union Hospital; Ningbo Medical Center Lihuili Hospital; Shanghai First Maternity and Infant Hospital; Shanghai 6th People's Hospital; Affiliated Hospital of Nantong University; Nanchang Third Hospital; Liaoning Cancer Hospital & Institute; The First Hospital of Jilin University
First posted
Oct 26, 2022

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
Female only, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to establish a prospective, multi-center platform research based on clinical subtypes to explore precision therapy in patients hormone-receptor-positive HER2-negative advanced breast cancer who had previously used CDK4/6 inhibitors.

Conditions

  • Breast Neoplasm
  • Breast Cancer
  • Hormone Receptor Positive Tumor
  • HER2-negative Breast Cancer
  • Advanced Breast Cancer

Interventions

  • PIK3CA inhibitorDrug

    PIK3CA inhibitor

  • AKT inhibitorDrug

    AKT inhibitor

  • CarrelizumabDrug

    Pd-1 mab

  • FamitinibDrug

    VEGFR inhibitor

  • FluzoparibDrug

    PARP inhibitor

  • DalpiciclibDrug

    CDK4/6 inhibitor

  • SHR-A1811Drug

    HER2 ADC

  • EverolimusDrug

    mTOR inhibior

  • Aromatase Inhibitors or FulvestrantDrug

    Letrozole/Anastrozole/Exemestane or Fulvestrant

  • GoserelinDrug

    For premenopause

  • TPCDrug

    Treatment of Physicians' Choice (albumin-paclitaxel, capecitabine, vinorelbine, and irbribulin)

  • SorafenibDrug

    RTK Inhibitor

  • ApatinibDrug

    Apatinib 250mg po qd

  • SHR-A1921Drug

    TROP2 ADC

  • SHR-A2102Drug

    NECTIN4 ADC

  • SHR-A2009Drug

    HER3 ADC

  • SHR-1167Drug

    PARP1i

  • SHR-6209Drug

    CDK4i

  • bevacizumabDrug

    bevacizumab

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Overall response rate (ORR)Time frame: Randomization until the first occurrence of disease progression or death from any cause, which ever occurs first, through the end of study (approximately 3 years)

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Breast cancer institute of Fudan University Cancer Hospital

    Shanghai, Shanghai Municipality, China · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.